Trial Profile
A Phase 1/2, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 15 Feb 2024
Price :
$35
*
At a glance
- Drugs Enasidenib (Primary)
- Indications Acute myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Celgene Corporation
- 08 Feb 2024 Status changed from active, no longer recruiting to completed.
- 08 Mar 2023 Planned End Date changed from 31 Dec 2022 to 29 Dec 2023.
- 10 May 2022 Planned End Date changed from 31 Dec 2020 to 31 Dec 2022.